ArticleClinical kidney journal2025
Heterogeneity of regional and national hospitalization burden of lupus nephritis and systemic lupus erythematous.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- National trends in hospitalisation, in-hospital mortality and resource use for SLE in Spain from 2016 to 2022.Lupus science & medicine · 2026Article
- Astragaloside IV Alleviates Systemic Lupus Erythematosus by Modulating ITGB1/PTK2/p38 Pathway: Integrated Network Pharmacology and Experimental Validation.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differences between regional healthcare systems in the in-hospital burden and care of systemic lupus erythematosus (SLE) and lupus nephritis (LN) are poorly characterized. Their analysis may provide benchmarking opportunities that improve the quality and sustainability of care. Methods: We retrospectively investigated the hospitalization burden of SLE and LN in 2019-2021 across Spanish regional healthcare systems using the Spanish National Hospital Discharge Records database (RAE-CMBD) and National Statistics Institute (INE) data. Results: Of 66 262 724 hospitalization episodes from 644 public and private hospitals, 10 781 had a primary diagnosis of SLE, of which 2481 (23%) were for LN. The mean annual nationwide hospitalization case incidence was 70.61 and 1.75 per 100 000 population for SLE and LN, respectively. Regional differences were large: 48.0-fold and 6.9-fold between regions with the highest and lowest incidence for SLE and LN, respectively. In multivariate analysis, net household income and percentage of foreign-born population were associated with the number of SLE and LN hospitalization episodes. Internal medicine managed 28% of SLE and 15% of LN hospitalizations, nephrology 14% and 56% and rheumatology 23% and 11%, respectively, but there were large regional differences. The mean SLE and LN stays were 8.85 and 6.92 days (5.47 and 5.41 for nephrology and 11.18 and 11.83 for internal medicine), respectively. The average all patient refined diagnosis related groups (APR-DRGs) cost per episode was €2408 for SLE and €3563 for LN. The average yearly costs were €167 985 per million population (pmp) for SLE hospitalizations (4.32-fold differences between regions) and €60 825 pmp for LN hospitalizations (4.20-fold differences between regions). Large differences between regions were observed in the cost burden pmp relative to household income (4.70-fold for LN and 4.13-fold for SLE). Conclusion: In real-world clinical practice, the burden of in-hospital care of LN and SLE is heterogeneous across and within regional healthcare systems, offering the opportunity to benchmark best practice, optimize care and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.